RoslinCT announces the construction of a new Cell & Gene therapy manufacturing facility.
Released: Friday 26th June 2020
RoslinCT announces the construction of a new Cell & Gene therapy manufacturing facility.
RoslinCT - a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) - announces initiation of construction for the expansion of their new manufacturing centre. The new state of the art 1,600 m2 facility will operate to US and EU GMP standards and will become an innovative hub for the manufacture of cell and gene therapy products. This expansion accelerates our development and manufacturing capability, promising to bring next-generation treatments to patients globally.
The new custom-designed facility will encompass five clean rooms, warehousing and offices for all supporting activities and will include a dedicated training lab that is set to be the new home of our Training Academy. This new facility will also allow us to grow our talent pool by creating new opportunities in order to shape an attractive, world-leading biotechnology hub. Our growth plan covers a wide range of roles welcoming scientists and professionals from across the globe to join our dynamic team. We have exciting and ambitious plans for growth and the expansion of the current RoslinCT facility will mark a new promising era for the company.
“As a leading CDMO in the field of cell and gene therapy, starting this expansion is a significant milestone in the growth of the business as we expand our global supply. Despite the Covid-19 pandemic the cell and gene therapy sector continues to grow and prosper. Beyond this new facility, we have ambitious plans for further expansion providing even greater capacity and increasing our gene therapy service offering. I am very proud of the RoslinCT team and how they have responded to recent challenges, enabling our start the expansion on site and continuing to support for our customers through clinical trials and beyond” said Janet Downie, CEO of RoslinCT
“These state-of-the-art facilities will more than double our capacity to deliver game-changing cell and gene therapies for our customers and patients. Key to our success is our people and as we move through this phase of growth, we are developing a team and infrastructure to take the business forward. I’m excited about providing such a great opportunity for our team and for attracting new talent to the business” said Kevin Bruce, Chief Operating Officer of RoslinCT.
Our new facility is located within the Edinburgh BioQuarter, a leading global destination for healthcare delivery, ground-breaking medical research and life sciences innovation and entrepreneurship.
For more information, please contact:
Katerina Tsita
Marketing Executive
Tel: +44 (0)131 658 5189
Email: Katerina.Tsita@roslinct.com
Web: www.roslinct.com
About RoslinCT
RoslinCT is a leading Contract Development and Manufacturing Organisation (CDMO), offering a range of integrated services from technology transfer, process and assay development through to GMP manufacturing, storage, QP certification and batch release of cell-based therapies for clinical trials.
RoslinCT has the vision to lead the field in cell and gene therapy manufacturing and be the global partner of choice, building success on expert knowledge, progressive partnerships and with the drive to deliver life-changing cell-based products to patients in need. This together with a passion for innovation and a flexible and personalised
For more information please visit http://www.roslinct.com
